111 related articles for article (PubMed ID: 25668044)
1. The importance of surgical staging in women with uterine serous carcinoma: experience in a single institution reveals a survival benefit.
Ball A; Chu P; Ghatage P; Nation J; Nelson G
J Obstet Gynaecol Can; 2014 Dec; 36(12):1085-1092. PubMed ID: 25668044
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.
Erickson BK; Najjar O; Damast S; Blakaj A; Tymon-Rosario J; Shahi M; Santin A; Klein M; Dolan M; Cimino-Mathews A; Buza N; Ferriss JS; Stone RL; Khalifa M; Fader AN
Gynecol Oncol; 2020 Oct; 159(1):17-22. PubMed ID: 32709539
[TBL] [Abstract][Full Text] [Related]
3. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.
Bristow RE; Asrari F; Trimble EL; Montz FJ
Gynecol Oncol; 2001 May; 81(2):279-86. PubMed ID: 11330963
[TBL] [Abstract][Full Text] [Related]
4. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of patients with uterine serous carcinoma using the revised FIGO staging system.
Seward S; Ali-Fehmi R; Munkarah AR; Semaan A; Al-Wahab ZR; Elshaikh MA; Cote ML; Morris RT; Bandyopadhyay S
Int J Gynecol Cancer; 2012 Mar; 22(3):452-6. PubMed ID: 22274544
[TBL] [Abstract][Full Text] [Related]
6. Stage I noninvasive and minimally invasive uterine serous carcinoma: comprehensive staging associated with improved survival.
Giuntoli RL; Gerardi MA; Yemelyanova AV; Ueda SM; Fleury AC; Diaz-Montes TP; Bristow RE
Int J Gynecol Cancer; 2012 Feb; 22(2):273-9. PubMed ID: 22146771
[TBL] [Abstract][Full Text] [Related]
7. Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?
Winer I; Ahmed QF; Mert I; Bandyopadhyay S; Cote M; Munkarah AR; Hussein Y; Al-Wahab Z; Elshaikh MA; Alosh B; Schultz DS; Mahdi H; Nucci MR; Van de Vijver KK; Morris RT; Oliva E; Ali-Fehmi R
Int J Gynecol Pathol; 2015 Jan; 34(1):47-56. PubMed ID: 25473753
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis, treatment and prognosis of uterine serous carcinoma].
Zhang F; Deng LS; Li B; Huang MN; Li XG; Zhang R; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):848-856. PubMed ID: 33355760
[No Abstract] [Full Text] [Related]
9. Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma.
Desai NB; Kollmeier MA; Makker V; Levine DA; Abu-Rustum NR; Alektiar KM
Gynecol Oncol; 2014 Oct; 135(1):49-53. PubMed ID: 25084509
[TBL] [Abstract][Full Text] [Related]
10. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
[TBL] [Abstract][Full Text] [Related]
11. Uterine serous carcinoma: a comparison of therapy for advanced-stage disease.
Gehrig PA; Morris DE; Van Le L
Int J Gynecol Cancer; 2004; 14(3):515-20. PubMed ID: 15228426
[TBL] [Abstract][Full Text] [Related]
12. Factors Affecting Overall Survival in Premenopausal Women With Uterine Leiomyosarcoma: A Retrospective Analysis With Long-Term Follow-Up.
Singh N; Al-Ruwaisan M; Batra A; Itani D; Ghatage P
J Obstet Gynaecol Can; 2020 Dec; 42(12):1483-1488. PubMed ID: 32900677
[TBL] [Abstract][Full Text] [Related]
13. Impact of tubal ligation on routes of dissemination and overall survival in uterine serous carcinoma.
Ayeni TA; Bakkum-Gamez JN; Mariani A; McGree ME; Weaver AL; AlHilli MM; Martin JR; Keeney GL; Dowdy SC; Podratz KC
Gynecol Oncol; 2013 Jan; 128(1):71-76. PubMed ID: 23127971
[TBL] [Abstract][Full Text] [Related]
14. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy.
Tate K; Yoshida H; Ishikawa M; Uehara T; Ikeda SI; Hiraoka N; Kato T
J Gynecol Oncol; 2018 May; 29(3):e34. PubMed ID: 29533019
[TBL] [Abstract][Full Text] [Related]
16. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients.
Grice J; Ek M; Greer B; Koh WJ; Muntz HG; Cain J; Tamimi H; Stelzer K; Figge D; Goff BA
Gynecol Oncol; 1998 Apr; 69(1):69-73. PubMed ID: 9571001
[TBL] [Abstract][Full Text] [Related]
17. Population-based treatment and outcomes of Stage I uterine serous carcinoma.
van der Putten LJ; Hoskins P; Tinker A; Lim P; Aquino-Parsons C; Kwon JS
Gynecol Oncol; 2014 Jan; 132(1):61-4. PubMed ID: 24219983
[TBL] [Abstract][Full Text] [Related]
18. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study.
Mahdi H; Elshaikh MA; DeBenardo R; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; Moslemi-Kebria M
Gynecol Oncol; 2015 May; 137(2):239-44. PubMed ID: 25641568
[TBL] [Abstract][Full Text] [Related]
19. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
[TBL] [Abstract][Full Text] [Related]
20. Lymphadenectomy as a prognostic marker in uterine non-endometrioid carcinoma.
Mylonas I; Schindlbeck C
Arch Gynecol Obstet; 2012 Jan; 285(1):207-14. PubMed ID: 21538008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
